Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $6.11 Consensus Target Price from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average recommendation of “Hold” by the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $6.11.

Several equities analysts have issued reports on STRO shares. Citizens Jmp downgraded Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, March 14th. Bank of America reduced their price target on shares of Sutro Biopharma from $1.00 to $0.80 and set an “underperform” rating on the stock in a research report on Monday, May 19th. Wedbush cut shares of Sutro Biopharma from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $8.00 to $2.00 in a research report on Friday, March 14th. HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Sutro Biopharma in a research note on Tuesday, April 29th. Finally, Piper Sandler raised Sutro Biopharma from a “neutral” rating to an “overweight” rating and set a $2.00 price objective on the stock in a report on Monday.

Sutro Biopharma Trading Up 0.5%

Shares of NASDAQ STRO opened at $0.79 on Monday. The firm has a market capitalization of $67.04 million, a price-to-earnings ratio of -0.27 and a beta of 1.70. Sutro Biopharma has a one year low of $0.52 and a one year high of $5.17. The business has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $1.37.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.28). Sutro Biopharma had a negative return on equity of 347.60% and a negative net margin of 373.66%. The business had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. On average, research analysts anticipate that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sutro Biopharma

Large investors have recently modified their holdings of the business. Strs Ohio bought a new stake in Sutro Biopharma during the 1st quarter worth approximately $99,000. Acadian Asset Management LLC increased its position in shares of Sutro Biopharma by 78.9% during the first quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company’s stock worth $2,037,000 after acquiring an additional 1,382,661 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after acquiring an additional 1,206,330 shares during the period. Vestal Point Capital LP raised its holdings in shares of Sutro Biopharma by 1.2% during the first quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company’s stock worth $1,692,000 after acquiring an additional 30,000 shares during the period. Finally, RA Capital Management L.P. bought a new stake in Sutro Biopharma in the 1st quarter valued at $2,885,000. 96.99% of the stock is currently owned by institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.